Qualifications
MD, PhD
Personal/work Web page addresses
http://www.tm.nagasaki-u.ac.jp/hiraken/
Research gate or Linked-in account links
https://www.researchgate.net/profile/Kenji_Hirayama
Affiliation(s)
Department of Immunogenetics, Institute of Tropical Medicine (NEKKEN), Nagasaki University
Background
- 2001-： Professor, NEKKEN, Nagasaki University
- 1995-2001：Professor, Saitama Medical University
- 1989-92: Research Fellow, Harvard School of Public Health
- 1985-89: Medical Institute of Bioregulation, Kyushu University
- 1981-85: PhD course, Human Genetics, Medical Research Institute, Tokyo Medical and Dental University
Teaching
Current roles: Course Director of Health Innovation, Responsible for Immunology and Biotechnology courses
Teaching experience: Course Director of Master of Tropical Medicine, Nagasaki University Graduate school of Biomedical Science. Medical Parasitology, Clinical Immunology, Tropical Infectious diseases, Tropical Public Health, Research Ethics, Vaccinology, Clinical Product Development
Research
Vaccine development for malaria, Dengue, and Chagas Disease using DNA or recombinant vaccine. (Hisamitsu, Pasteur Paris, European Vaccine Initiative)
Drug development for malaria and trypanosomiasis using compound designing or herbal medicine. (Astellas, National Institute of Advanced Industrial Science and Technology, Institute of Natural Medicine Toyama University, Thammasat University)
HLA regulated Immune responsiveness against malaria, dengue, Chagas and Schistosomiasis. (Tokyo Med Dent University, Research Institute of Tropical Medicine, Philippines, Pasteur Institute Ho Chi Minh, Kenya Medical Research Institute)
http://www.tm.nagasaki-u.ac.jp/hiraken/english/index.html
The country/countries where you work currently
- France
- Germany
- UK
- Thailand
- Vietnam
- Myanmar
- Philippines
- Kenya
- Bolivia
- Paraguay
- DRCongo
Five Key Recent Publications
- Kinoshita T, Espino F, Bunagan R, Lim D, Daga C, Parungao S, Balderian A, Micu K, Laborera R, Basilio R, Inobaya M, Baquilod M, Dy M, Chiba H, Matsumoto T, Nakayama T, Kita K, Hirayama K. First malaria in pregnancy followed in Philippine real-world setting: proof-of-concept of probabilistic record linkage between disease surveillance and hospital administrative data. Trop Med Health. 2024; 52(1):17.
- Nakamae S, Miyagawa S, Ogawa K, Kamiya M, Taniguchi M, Ono A, Kawaguchi M, Teklemichael AA, Jian JY, Araki T, Katagami Y, Mukai H, Annoura T, Yui K, Hirayama K,Kawakami S, Mizukami S. Induction of liver-resident memory T cells and protection at liver-stage malaria by mRNA-containing lipid nanoparticles. Front Immunol. 2023; 14:1116299.
- Mercado ES, Espino FE, Perez ML, Bilar JM, Bajaro JD, Huy NT, Baello BQ, Kikuchi M, Hirayama K. HLA-A*33:01 as protective allele for severe dengue in a population of Filipino children. PLoS One. 2015 Feb 6;10(2):e0115619. doi: 10.1371/journal.pone.0115619. eCollection 2015.
- Fujii Y, Kaneko S, Nzou SM, Mwau M, Njenga SM, Tanigawa C, Kimotho J, Mwangi AW, Kiche I, Matsumoto S, Niki M, Osada-Oka M, Ichinose Y, Inoue M, Itoh M, Tachibana H, Ishii K, Tsuboi T, Yoshida LM, Mondal D, Haque R, Hamano S, Changoma M, Hoshi T, Kamo K, Karama M, Miura M, Hirayama K. Serological surveillance development for tropical infectious diseases using simultaneous microsphere-based multiplex assays and finite mixture models. PLoS Negl Trop Dis. 2014 Jul 31;8(7):e3040. doi: 10.1371/journal.pntd.0003040. eCollection 2014.
- Iglesias Rodríguez IM, Miura S, Maeda T, Imai K, Smith C, Vasquez Velasquez C, Honda S, Hirayama K.Analysis of the Chagas disease situation in Japan: a cross sectional study and cost-effectiveness analysis of a Chagas disease screening program. Lancet Reg Health West Pac. 2022; 31:100574.
Message
I am teaching Biotechnology, Immunology with Prof Yui and Research Ethics with Prof Juntra. My research area is immunology, human genetics and product development in tropical infectious diseases, and I am currently interested in research that contributes to the prevention and treatment of tropical infectious diseases with high morbidity and mortality. Production of vaccines and drugs has been my dream ever since I decided to be a doctor. I realized that such research should be pursued as a joint team gathering the forces of academia, public domains and private sectors, the so called PPP. For more than ten years, I have been involved in such projects for the control of malaria, dengue fever, Chagas disease and schistosomiasis. I hope you will be interested in our activity.